{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:10:45Z","timestamp":1789575045324,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Liver metastases, a hallmark of systemic disease, carry a poor prognosis despite advancements in systemic therapies. Stereotactic body radiation therapy (SBRT) has emerged as a promising local treatment, offering durable tumor control with minimal toxicity. However, the optimal dosimetric strategies to maximize outcomes remain an area of active investigation. This retrospective study evaluated 76 patients with 101 liver metastases treated with SBRT between November 2012 and June 2024. Dosimetric parameters were analyzed, including prescribed dose (PD) and dose metrics for planning target volume (PTV) and gross tumor volume (GTV), with doses converted to equivalent doses in 2\u00a0Gy fractions (EQD2, \u03b1\/\u03b2\u2009=\u200910). Tumor control probability (TCP) models and survival outcomes were assessed, with a focus on the prognostic impact of dosimetric and clinical factors. Median overall survival (OS) was 33\u00a0months, with 1-year and 3-year OS rates of 74.1% and 39.4%, respectively. Freedom from local progression (FFLP) was 82.5% at 12\u00a0months. PD emerged as the strongest independent predictor of local control, with an optimal threshold of 77.44\u00a0Gy EQD2 significantly improving 1-year FFLP rates (96.8% vs. 67.2%; p\u2009=\u20090.007). Advanced motion management techniques, including internal breath-hold (iBH) with image-guided radiotherapy (IGRT), demonstrated superior local control outcomes. Predictive modeling confirmed PD as the most robust dosimetric metric, correlating with a high TCP and outperforming other dose metrics. Toxicity was minimal, with only 3.9% experiencing grade\u2009\u2265\u20093 adverse events. SBRT represents a highly effective and safe approach for liver metastases, with PD and advanced imaging emerging as pivotal determinants of tumor control. These findings underscore the importance of precise dosimetric planning and motion management in optimizing SBRT outcomes. This study provides a robust framework for personalized treatment strategies, contributing to the integration of SBRT as a cornerstone in the multidisciplinary management of liver metastases.<\/jats:p>","DOI":"10.1007\/s10585-025-10344-3","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T06:17:54Z","timestamp":1745648274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing tumor control in liver metastases treated with SBRT: dosimetric predictors and clinical outcomes from a single-center analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Lisa","family":"Seyfried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Eble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Allam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"10344_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2020.101760","volume":"67","author":"SR Horn","year":"2020","unstructured":"Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ et al (2020) Epidemiology of liver metastases. Cancer Epidemiol 67:101760","journal-title":"Cancer Epidemiol"},{"issue":"34","key":"10344_CR2","doi-asserted-by":"publisher","first-page":"55368","DOI":"10.18632\/oncotarget.10552","volume":"7","author":"J de Ridder","year":"2016","unstructured":"de Ridder J, de Wilt JHW, Simmer F, Overbeek L, Lemmens V, Nagtegaal I et al (2016) Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget 7(34):55368\u201355376","journal-title":"Oncotarget"},{"issue":"15","key":"10344_CR3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1177\/1535370216658144","volume":"241","author":"AM Clark","year":"2016","unstructured":"Clark AM, Ma B, Taylor DL, Griffith L, Wells A (2016) Liver metastases: microenvironments and ex-vivo models. Exp Biol Med 241(15):1639","journal-title":"Exp Biol Med"},{"issue":"4","key":"10344_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1055\/a-0721-1947","volume":"191","author":"TJ Vogl","year":"2019","unstructured":"Vogl TJ, Pereira PL, Helmberger T, Schreyer AG, Schmiegel W, Fischer S et al (2019) Updated S3 guidelines\u2014diagnosis and treatment of colorectal carcinoma: relevance for radiological diagnosis and intervention. Rofo 191(4):298\u2013310","journal-title":"Rofo"},{"issue":"2","key":"10344_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","volume":"35","author":"A Cervantes","year":"2024","unstructured":"Cervantes A, Martinelli E (2024) Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Ann Oncol 35(2):241\u2013243","journal-title":"Ann Oncol"},{"key":"10344_CR6","unstructured":"Adam M, Chang GJ, Chen YJ, Ciombor KK, Cohen SA, Deming D, et al. NCCN Guidelines Version 5.2024 Colon Cancer Continue NCCN Guidelines Panel Disclosures. 2024"},{"issue":"7","key":"10344_CR7","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/02841860600904870","volume":"45","author":"BD Kavanagh","year":"2006","unstructured":"Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD et al (2006) Interim analysis of a prospective phase I\/II trial of SBRT for liver metastases. Acta Oncol 45(7):848\u2013855","journal-title":"Acta Oncol"},{"issue":"5","key":"10344_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","volume":"62","author":"TE Schefter","year":"2005","unstructured":"Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62(5):1371\u20131378","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10344_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","volume":"99","author":"A McPartlin","year":"2017","unstructured":"McPartlin A, Swaminath A, Wang R, Pintilie M, Brierley J, Kim J et al (2017) Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys 99(2):388\u2013395","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10344_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.radonc.2017.01.018","volume":"123","author":"RB Goody","year":"2017","unstructured":"Goody RB, Brade AM, Wang L, Craig T, Brierley J, Dinniwell R et al (2017) Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. Radiother Oncol 123(2):234\u2013239","journal-title":"Radiother Oncol"},{"issue":"1","key":"10344_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12943-024-01970-8","volume":"23","author":"A Levy","year":"2024","unstructured":"Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME et al (2024) An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. Mol Cancer 23(1):61","journal-title":"Mol Cancer"},{"key":"10344_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110240","volume":"195","author":"D Franceschini","year":"2024","unstructured":"Franceschini D, Franzese C, Comito T, Ilieva MB, Spoto R, Marzo AM et al (2024) Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (SBRT) for medically inoperable lung and liver oligometastases from breast cancer. Radiother Oncol 195:110240","journal-title":"Radiother Oncol"},{"key":"10344_CR13","doi-asserted-by":"crossref","unstructured":"Franzese C, Louie A V., Kotecha R, Zhang Z, Guckenberger M, Kim MS et al (2024) Stereotactic body radiation therapy for liver metastases: systematic review and meta-analysis with International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines. Pract Radiat Oncol","DOI":"10.1016\/j.prro.2024.09.011"},{"issue":"10","key":"10344_CR14","doi-asserted-by":"publisher","first-page":"9230","DOI":"10.3390\/curroncol30100667","volume":"30","author":"S Mheid","year":"2023","unstructured":"Mheid S, Allen S, Ng SSW, Hall WA, Sanford NN, Aguilera TA et al (2023) Local control following stereotactic body radiation therapy for liver oligometastases: lessons from a quarter century. Curr Oncol 30(10):9230","journal-title":"Curr Oncol"},{"issue":"1","key":"10344_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-018-1185-9","volume":"13","author":"M Scorsetti","year":"2018","unstructured":"Scorsetti M, Comito T, Clerici E, Franzese C, Tozzi A, Iftode C et al (2018) Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol 13(1):1\u201310. https:\/\/doi.org\/10.1186\/s13014-018-1185-9","journal-title":"Radiat Oncol"},{"issue":"1","key":"10344_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13014-022-02033-2","volume":"17","author":"P Hoegen","year":"2022","unstructured":"Hoegen P, Zhang KS, Tonndorf-Martini E, Weykamp F, Regnery S, Naumann P et al (2022) MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Radiat Oncol 17(1):59","journal-title":"Radiat Oncol"},{"key":"10344_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejmp.2019.08.003","volume":"65","author":"J Boda-Heggemann","year":"2019","unstructured":"Boda-Heggemann J, Sihono DSK, Streb L, Mertens L, Vogel L, Stieler F et al (2019) Ultrasound-based repositioning and real-time monitoring for abdominal SBRT in DIBH. Phys Med 65:46\u201352","journal-title":"Phys Med"},{"issue":"1116","key":"10344_CR18","doi-asserted-by":"publisher","first-page":"20200859","DOI":"10.1259\/bjr.20200859","volume":"93","author":"LB Stick","year":"2020","unstructured":"Stick LB, Vogelius IR, Risum S, Josipovic M (2020) Intrafractional fiducial marker position variations in stereotactic liver radiotherapy during voluntary deep inspiration breath-hold. Br J Radiol 93(1116):20200859","journal-title":"Br J Radiol"},{"key":"10344_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tipsro.2023.100223","volume":"28","author":"M Turna","year":"2023","unstructured":"Turna M, K\u00fc\u00e7\u00fckmorko\u00e7 E, Rzazade R, Do\u011fu Cano\u011flu M, K\u00fc\u00e7\u00fck N, Caglar HB (2023) Feasibility and tolerability of breath-hold in liver stereotactic body radiotherapy with surface guided radiotherapy. Tech Innov Patient Support Radiat Oncol 28:100223","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10344_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tipsro.2018.04.001","volume":"7","author":"M Mast","year":"2018","unstructured":"Mast M, Kouwenhoven E, Roos J, van Geen S, van Egmond J, van Santvoort J et al (2018) Two years\u2019 experience with inspiration breath-hold in liver SBRT. Tech Innov Patient Support Radiat Oncol 7:1\u20135","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"2","key":"10344_CR21","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/S1470-2045(20)30034-6","volume":"21","author":"JS Witt","year":"2020","unstructured":"Witt JS, Rosenberg SA, Bassetti MF (2020) MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol 21(2):e74-82","journal-title":"Lancet Oncol"},{"issue":"4","key":"10344_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ijrobp.2018.04.016","volume":"102","author":"PJ Keall","year":"2018","unstructured":"Keall PJ, Nguyen DT, O\u2019Brien R, Zhang P, Happersett L, Bertholet J et al (2018) Review of real-time 3-dimensional image guided radiation therapy on standard-equipped cancer radiation therapy systems: are we at the tipping point for the era of real-time radiation therapy? Int J Radiat Oncol Biol Phys 102(4):922\u2013931","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10344_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00066-020-01603-1","volume":"196","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Baus WW, Blanck O, Combs SE, Debus J, Engenhart-Cabillic R et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Strahlenther Onkol 196(5):417\u2013420. https:\/\/doi.org\/10.1007\/s00066-020-01603-1","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"10344_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","volume":"195","author":"L Wilke","year":"2019","unstructured":"Wilke L, Andratschke N, Blanck O, Brunner TB, Combs SE, Grosu AL et al (2019) ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol 195(3):193\u2013198. https:\/\/doi.org\/10.1007\/s00066-018-1416-x","journal-title":"Strahlenther Onkol"},{"key":"10344_CR25","doi-asserted-by":"crossref","unstructured":"McPartlin A, Swaminath A, Wang R, Pintilie M, Brierley J, Kim J, et al. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. International Journal of Radiation Oncology*Biology*Physics. 2017;99(2):388\u201395.","DOI":"10.1016\/j.ijrobp.2017.04.010"},{"issue":"5","key":"10344_CR26","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ijrobp.2020.11.045","volume":"109","author":"A M\u00e9ndez Romero","year":"2021","unstructured":"M\u00e9ndez Romero A, Schillemans W, van Os R, Koppe F, Haasbeek CJ, Hendriksen EM et al (2021) The Dutch-Belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases. Int J Radiat Oncol Biol Phys 109(5):1377\u20131386","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10344_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/hpb.12044","volume":"15","author":"B Berber","year":"2013","unstructured":"Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT et al (2013) Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB 15(11):851\u2013857","journal-title":"HPB"},{"issue":"1","key":"10344_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4191-2","volume":"18","author":"N Andratschke","year":"2018","unstructured":"Andratschke N, Alheid H, Allg\u00e4uer M, Becker G, Blanck O, Boda-Heggemann J et al (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):1\u201311","journal-title":"BMC Cancer"},{"issue":"1","key":"10344_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-018-0969-2","volume":"13","author":"A Mahadevan","year":"2018","unstructured":"Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D\u2019Ambrosio D et al (2018) Stereotactic Body Radiotherapy (SBRT) for liver metastasis\u2014clinical outcomes from the international multi-institutional RSSearch\u00ae Patient Registry. Radiat Oncol 13(1):1\u201311. https:\/\/doi.org\/10.1186\/s13014-018-0969-2","journal-title":"Radiat Oncol"},{"issue":"9","key":"10344_CR30","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00432-020-03223-9","volume":"146","author":"L Nicosia","year":"2020","unstructured":"Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F et al (2020) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146(9):2351\u20132358. https:\/\/doi.org\/10.1007\/s00432-020-03223-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10344_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-022-00342-z","volume":"7","author":"FA Zeineddine","year":"2023","unstructured":"Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A et al (2023) Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precis Oncol 7(1):1\u20139","journal-title":"npj Precis Oncol"},{"issue":"2","key":"10344_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.semradonc.2022.11.008","volume":"33","author":"SL Lee","year":"2023","unstructured":"Lee SL, Bassetti MF, Rusthoven CG (2023) The role of stereotactic body radiation therapy in the management of liver metastases. Semin Radiat Oncol 33(2):181\u2013192","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"10344_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jncc.2022.06.004","volume":"2","author":"K Alrabiah","year":"2022","unstructured":"Alrabiah K, Liao G, Shen Q, Chiang CL, Dawson LA (2022) The evolving role of radiation therapy as treatment for liver metastases. J Natl Cancer Center 2(3):183","journal-title":"J Natl Cancer Center"},{"issue":"1","key":"10344_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","volume":"110","author":"N Ohri","year":"2021","unstructured":"Ohri N, Tom\u00e9 WA, M\u00e9ndez Romero A, Miften M, Ten Haken RK, Dawson LA et al (2021) Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 110(1):188\u2013195","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10344_CR35","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1007\/s00330-015-3779-z","volume":"25","author":"A Gillams","year":"2015","unstructured":"Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M et al (2015) Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Fronti\u00e8res meeting 2013. Eur Radiol 25(12):3438\u20133454","journal-title":"Eur Radiol"},{"issue":"5","key":"10344_CR36","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","volume":"95","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B et al (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 95(5):1399","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10344-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T10:09:53Z","timestamp":1749550193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["10344"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10344-3","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}